These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis. Silver LH, Woodside AM, Montgomery DB. Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S55-63. PubMed ID: 16257311 [Abstract] [Full Text] [Related]
24. Oral clindamycin 300 mg BID compared with oral amoxicillin/clavulanic acid 1 g BID in the outpatient treatment of acute recurrent pharyngotonsillitis caused by group a beta-hemolytic streptococci: an international, multicenter, randomized, investigator-blinded, prospective trial in patients between the ages of 12 and 60 years. Mahakit P, Vicente JG, Butt DI, Angeli G, Bansal S, Zambrano D. Clin Ther; 2006 Jan; 28(1):99-109. PubMed ID: 16490583 [Abstract] [Full Text] [Related]
25. Clinical evaluation of ophthalmic lomefloxacin 0.3% in comparison with fortified cefazolin and gentamicin ophthalmic solutions in the treatment of presumed bacterial keratitis. Erjongmanee S, Kasetsuwan N, Phusitphoykai N, Puangsricharern V, Pariyakanok L. J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S83-90. PubMed ID: 16083168 [Abstract] [Full Text] [Related]
29. Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis. Gotfried M, Notario G, Spiller J, Palmer R, Busman T. Curr Med Res Opin; 2005 Feb; 21(2):245-54. PubMed ID: 15801995 [Abstract] [Full Text] [Related]
30. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Tepedino ME, Heller WH, Usner DW, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock TL. Curr Med Res Opin; 2009 May; 25(5):1159-69. PubMed ID: 19323612 [Abstract] [Full Text] [Related]
31. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Shulman DG, Lothringer LL, Rubin JM, Briggs RB, Howes J, Novack GD, Hart K. Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491 [Abstract] [Full Text] [Related]
35. Once-daily ofloxacin otic solution versus neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa. Schwartz RH. Curr Med Res Opin; 2006 Sep; 22(9):1725-36. PubMed ID: 16968576 [Abstract] [Full Text] [Related]